NeuroMetrix Announces Initial Commercial Shipment of SENSUS™ Pain Management System
WALTHAM, Mass.--(BUSINESS WIRE)--Jan. 7, 2013--
NeuroMetrix, Inc. (Nasdaq: NURO),
www.neurometrix.com,
a medical device company focused on the diagnosis and treatment of the
neurological complications of diabetes, reported today that it had
initiated commercial shipment of its SENSUS Pain Management System which
received final
FDA clearance on
November 28, 2012. SENSUS is a
transcutaneous electrical nerve stimulator intended for the symptomatic
relief and management of chronic intractable pain. It offers physicians
and their patients advanced nerve stimulation technology in a light
weight, low profile device worn on the upper calf that is activated by
the press of a single button.
“SENSUS was designed to address the clinical and lifestyle needs of
people with diabetes. Therefore, we believe that physicians treating
patients with painful diabetic neuropathy, a severe and debilitating
form of chronic pain, may find SENSUS to be a useful therapeutic
option,” said Shai N. Gozani M.D., Ph.D., President and Chief Executive
Officer of NeuroMetrix. “We are pleased to be partnering with a growing
network of durable medical equipment suppliers who will be responsible
for physician detailing, supplying product to patients, and insurance
billing. This will allow us to focus on our areas of expertise which
include product development, marketing programs, and clinical studies.”
About NeuroMetrix
NeuroMetrix is an innovative medical device company that develops and
markets home use and point-of-care devices for the treatment and
management of diabetic neuropathies, which affect over 50% of people
with diabetes. If left untreated, diabetic neuropathies trigger foot
ulcers that may require amputation, cause disabling chronic pain, and
increase the risk of falling in the elderly. The annual cost of diabetic
neuropathies has been estimated at $14 billion in the United States. The
company’s products are used by physicians and managed care organizations
to optimize patient care and reduce healthcare costs. The company
markets the NC-stat® DPNCheck™ device, which is a rapid,
accurate, and quantitative point-of-care test for diabetic neuropathy.
This product is used to detect diabetic neuropathy at an early stage and
to guide treatment. The company also markets the SENSUS™ Pain Management
System for treating chronic pain, focusing on physicians managing
patients with painful diabetic neuropathy. The company has additional
therapeutic products in its pipeline. For more information, please visit http://www.neurometrix.com.
Source: NeuroMetrix, Inc.
NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and
Chief Financial Officer
neurometrix.ir@neurometrix.com
